Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azenta, Inc.'s SEC filings document operating results, material events, governance matters and acquisition agreements for a life sciences solutions company built around cold-chain sample management and multiomics services. Recent Form 8-K disclosures include quarterly results and financial-condition updates, leadership and board changes, and the material definitive agreement under which Azenta UK Ltd acquired UK Biocentre.
The company’s proxy and annual-meeting filings describe director elections, advisory executive-compensation votes, equity incentive plan amendments and auditor ratification. Together with material-event reports, these filings provide formal disclosure on Azenta’s governance structure, capital-related authorizations, transaction terms and recurring public-company reporting obligations.
Azenta, Inc. director William L. Cornog made an indirect open-market purchase of 10,000 shares of common stock on May 18, 2026 at a weighted average price of $16.38 per share. The shares were bought through trusts he beneficially owns and controls, bringing his indirect holdings to 19,703 shares.
Azenta, Inc. executive Starr Ephraim, SVP, General Counsel & Secretary, reported a tax-related share disposition. On May 15, 2026, 3,621 shares of common stock were delivered at $16.02 per share to satisfy withholding taxes tied to the vesting of 12,593 restricted stock units. After this tax-withholding transaction, the reporting person directly holds 68,393 shares of Azenta common stock.
Koffey Quentin reported acquisition or exercise transactions in this Form 4 filing.
Azenta, Inc. director Quentin Koffey received an annual grant of 5,663 shares of common stock under the company’s 2020 Equity Incentive Plan for Board service. No cash was paid for this award, which was valued at $215,000 using a $37.97 reference share price.
Following the grant, Koffey directly holds 10,698 shares. An additional 4,611,752 shares are reported as indirectly owned through entities he ultimately controls, with beneficial ownership disclaimed except for his pecuniary interest.
Azenta, Inc. reported quarterly revenue of $144.8 million, roughly flat with the prior year, but recorded a large non‑cash goodwill impairment that pushed results deeply into the red. Operating loss reached $165.8 million, driven by a $149.1 million impairment related to its Multiomics and Sample Management Solutions reporting units.
From continuing operations, Azenta posted a net loss of $157.0 million, compared with a loss of $19.8 million a year earlier, and total net loss was $160.8 million. The B Medical Systems business remains classified as discontinued operations and held for sale; a planned $63.0 million sale to Thelema has been delayed because Thelema has not yet secured financing, although a $9.0 million deposit has been received and the share purchase agreement remains in effect.
Azenta closed the acquisition of UK Biocentre for about $27.5 million net of cash acquired, adding U.K. sample management capabilities and recording $5.1 million of goodwill. The company ended the quarter with $234.0 million in cash and cash equivalents and $324.3 million in marketable securities, providing sizable liquidity despite restructuring costs and ongoing transformation initiatives.
Azenta, Inc. reported second quarter fiscal 2026 revenue from continuing operations of $145 million, up 1% year over year, while organic revenue fell 3%. The company posted a GAAP net loss of $160.8 million, or ($3.49) per diluted share, driven largely by a $149 million non-cash goodwill impairment.
Adjusted EBITDA from continuing operations was $7.8 million, with a 5.4% margin, down from 8.5% a year earlier. Azenta cut its fiscal 2026 outlook, now guiding revenue between $603–$621 million, organic growth between down 2% and up 1%, and adjusted EBITDA margin from down about 125 basis points to flat versus fiscal 2025.
The company now expects free cash flow to improve 10–15% year over year, below its prior 30% target, and extended its long-range plan timeline from 2028 to 2029. Azenta ended the quarter with $565 million in cash, cash equivalents, restricted cash and marketable securities, and noted that the planned $63 million sale of B Medical Systems has been delayed as the buyer has not yet secured financing.
MARTIN WILLIAM E. III reported acquisition or exercise transactions in this Form 4 filing.
Azenta, Inc. granted President Multiomics William E. Martin III an award of 17,790 shares of common stock in the form of restricted stock units. The award is compensation under the company’s Equity Incentive Plan and no cash was paid to receive it.
The units vest over three years, with 33% vesting on April 18, 2027, 33% on April 18, 2028, and the remaining 33% on April 18, 2029. Following this grant, he directly holds 17,790 common shares linked to this award.
Azenta Inc reported that Vanguard Portfolio Management beneficially owns 2,466,192 shares of Common Stock, representing 5.35% of the class. The filing states Vanguard has sole dispositive power over 2,466,192 shares and sole voting power for 15,700 shares. The filing clarifies these holdings reflect accounts and affiliated advisory divisions managed by Vanguard Portfolio Management LLC.
Azenta, Inc. filed an initial Form 3 for William E. Martin III, who serves as President Multiomics. This filing establishes his status as a reporting officer of the company. The Form 3 shows no reported transactions or holdings in Azenta securities in this submission.
Azenta, Inc. announced a leadership transition in its Multiomics business. Ginger Zhou stepped down as President of Multiomics, and will remain an advisor through November 2026 under a consulting agreement with an initial fee of $103,500 paid in seven monthly installments.
Effective April 6, 2026, Azenta appointed William “Trey” E. Martin III as President, Multiomics, reporting to President and CEO John Marotta. His offer letter provides a $540,000 annual base salary, a target bonus equal to 80% of fiscal 2026 base salary, and a target long‑term equity award of about $1.7 million for 2026–2028, plus a potential $500,000 one‑time performance‑based equity grant. Azenta also amended offer letters for three executive officers to clarify and enhance severance and change‑in‑control benefits.
Azenta, Inc. reports that the planned sale of B Medical Systems S.À R.L. to Thelema S.À R.L., entered into through a definitive Sale and Purchase Agreement by Azenta Germany GmbH, did not close by the previously expected date of on or before March 31, 2026 because Thelema has not yet secured the required financing. Thelema has indicated it needs additional time to complete its financing arrangements, and the transaction remains subject to all closing conditions, including this financing condition. The parties have not amended or terminated the agreement, and Azenta is evaluating potential paths forward while emphasizing that there can be no assurance the transaction will be completed on a revised timeline or at all.